中基健康(000972) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was CNY 24,893,658.36, a 100.00% increase compared to the same period last year when it was CNY 0.00[3] - The net profit attributable to shareholders was a loss of CNY 4,986,755.44, an improvement from a loss of CNY 19,979,751.27 in the previous year, representing a 75.01% reduction in losses[3] - The net profit for the first quarter of 2022 was -4,995,605.10 RMB, compared to -19,988,180.25 RMB in the same period last year, showing an improvement of approximately 75%[18] - The total comprehensive income attributable to the parent company was -4,986,755.44 RMB, compared to -19,979,751.27 RMB in the previous year, indicating a significant reduction in losses[19] - The basic and diluted earnings per share were both -0.0065, an improvement from -0.0259 in the prior year[19] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 42,976,551.37, compared to a negative cash flow of CNY 25,390,802.51 in the same period last year[3] - Cash inflows from operating activities totaled 66,639,447.85 RMB, a substantial increase from 149,553.82 RMB in the same period last year[20] - Cash and cash equivalents at the end of the period amounted to 63,204,247.88 RMB, up from 10,548,551.53 RMB at the end of the previous year[21] - The company's cash and cash equivalents increased to CNY 63,204,247.88 from CNY 20,517,341.41 at the beginning of the year, representing a growth of approximately 207.5%[13] Assets and Liabilities - Total assets at the end of the reporting period were CNY 705,638,598.38, reflecting a 3.42% increase from CNY 682,336,138.44 at the end of the previous year[3] - Total liabilities rose to CNY 630,002,798.51 from CNY 601,705,050.46, an increase of approximately 4.7%[15] - The total equity attributable to shareholders decreased to CNY 70,537,058.61 from CNY 75,523,652.38, a decline of about 6.5%[16] Operating Costs and Expenses - Total operating costs for Q1 2022 amounted to CNY 30,042,866.00, an increase from CNY 20,017,428.02 in the previous year[17] - The company reported operating expenses of 23,662,896.48 RMB, slightly lower than 25,540,356.33 RMB in the previous year[20] - The company's management expenses decreased by 63.89% to CNY 6,739,952.29 from CNY 18,666,259.97 in the previous year due to reduced operational costs[7] Taxation and Subsidies - The company reported a 1820.85% increase in taxes and surcharges, amounting to CNY 116,403.27, compared to CNY 6,060.00 in the previous year[7] - The company received government subsidies amounting to CNY 89,218.29, marking a 100.00% increase from CNY 0.00 in the previous year[7] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,338[10] Inventory and Receivables - Accounts receivable decreased to CNY 126,855,321.23 from CNY 135,604,961.65, a decline of about 6.0%[13] - Inventory decreased to CNY 151,678,614.40 from CNY 160,812,447.35, reflecting a reduction of approximately 5.7%[14] Research and Development - The company incurred research and development expenses of CNY 458.49, with no expenses reported in the same period last year[17] Other Information - The company did not report any significant new product developments or market expansions during this quarter[22]